A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Selonsertib in subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • Hodge, Alex, (Primary Chief Investigator (PCI))

Project: Research

Project Description

NHMA HREC Ref number: HREC/17/SVHM/10
NMA SSA Ref number: SSA/17/MonH/237
Monash Health Ref: RES-17-0000-301X
SEO Code 920106 Endocrine Organs and Diseases (excl. Diabetes)
StatusActive
Effective start/end date9/11/1815/06/22